Metropolitan Life Insurance CO Rallybio Corp Transaction History

Metropolitan Life Insurance CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$4.31 - $8.89 $7,581 - $15,637	1,759 New	1,759 $9,000
Q4 2022 Jun 14, 2023	BUY	$4.67 - $14.86 $6,155 - $19,585	1,318 New	1,318 $8.66 Million
Q4 2022 Mar 30, 2023	BUY	$4.67 - $14.86 $709 - $2,258	152 Added 13.04%	1,318 $8,000
Q4 2022 Feb 15, 2023	BUY	$4.67 - $14.86 $709 - $2,258	152 Added 13.04%	1,318 $8,000
Q3 2022 Jun 14, 2023	BUY	$7.54 - $14.56 $8,791 - $16,976	1,166 New	1,166 $16.9 Million
Q3 2022 Mar 30, 2023	SELL	$7.54 - $14.56 $1,146 - $2,213	-152 Reduced 11.53%	1,166 $16,000
Q3 2022 Nov 14, 2022	BUY	$7.54 - $14.56 $8,791 - $16,976	1,166 New	1,166 $17,000

31.9M

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $31.8M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.